Boehringer Ingelheim to Work with Xybion’s Preclinical Gold Standard Solution, Pristima XD, to Enhance Lab Operations

Xybion Corporation announced today it is partnering with Boehringer Ingelheim to enhance process efficiency and data integrity in the Preclinical lab. This end to end preclinical gold standard solution helps with study planning, protocol, study execution, animal management, data management and regulatory submissions globally.

Boehringer Ingelheim’s mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned and has the freedom to pursue its long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good. As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.

The preclinical lab processes and data management are a critical part of Boehringer Ingelheim’s development, and the enhanced processes will make Good Laboratory Practice (GLP) as well as non-GLP studies more efficient. “Boehringer Ingelheim is excited to partner with Xybion and its end to end, fully unified solution, which will support us to run nearly the entire process from a single system. This improves the business user experience significantly, offers more flexibility and simplifies the IT ecosystem through a single platform instead of operating multiple systems,” says Dr. Robin Stierkat, IT Project manager of Boehringer Ingelheim.

Kamal Biswas, President and COO of Xybion says, “We are very excited to start this partnership. Xybion’s Pristima XD gold standard preclinical solution creates an end-to-end digital laboratory execution environment with connected workflows, innovative technology-driven automation, integrated instruments, and data management for the entire preclinical operation.”

“The cloud based Digital Lab platform helps Boehringer Ingelheim to achieve the goal to provide more health and improve the lives of both humans and animals, while reducing complexity in our own IT landscape,” adds Dr. Robin Stierkat.